Optimizing The Channel Strategy For Your CGT: Considerations For A Purpose-Built Approach

A distributor is only one piece of a cell and gene therapy channel strategy. The more consequential decisions often involve who can access a therapy, how product moves through the network, and how fulfillment is structured as demand grows. Explore how leading developers evaluate tradeoffs between exclusive, limited, and open networks, when drop-ship or inventory-based fulfillment makes sense, and what infrastructure providers need to support advanced therapies.

Learn how these interconnected decisions can help reduce operational complexity, support supply chain visibility, and position your therapy for both launch and long-term growth.